IL1RL1 Protein (AA 19-328)

Produktnummer ABIN2666553

Dieses Recombinant IL1RL1-Protein wird in HEK-293 Cells exprimiert.

Kurzübersicht für IL1RL1 Protein (AA 19-328) (ABIN2666553)

Target: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Flow Cytometry (FACS), Immunofluorescence (IF)

Reinheit: > 95 % , as determined by Coomassie stained SDS-PAGE.

Produktdetails

Proteineigenschaft: AA 19-328

Sterilität: 0.22 μm filtered

Endotoxin-Niveau:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: ED50 = 15 - 90 ng/ml, corresponding to a specific activity of 1.1 - 6.6 x 104 units/mg , as determined by inhibition of D10.G4.1 cell proliferation induced by IL-33.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Rekonstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20 °C to -70 °C. Stock solutions can also be prepared at 50 - 100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2 - 1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in 10 mM NaHPO4, 0.3M NaCl, and pH 7.2.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Antigendetails

Target: IL1RL1 (Interleukin 1 Receptor-Like 1 (IL1RL1))

Andere Bezeichnung: IL-1RL1

Hintergrund: IL-1RL1/ST2 was initially identified in stimulated Balc3T3 cells and is encoded by the IL-1RL1 gene that produces different isoforms by alternative splicing. In humans, four isoforms have been described: a membrane attached ST2L isoform and a soluble protein (sST2/ IL1RL-a) that lacks the transmembrane and cytoplasmic domains, which acts as a natural antagonist of IL-33. The other splice variants are ST2V and ST2LV. ST2V lacks the third immunoglobulin motif and C-terminal portion of ST2 and is mainly present in the gut whereas ST2LV does not have the transmembrane domain. The membrane isoform of ST2L (IL-1RL1) associates with IL-1 receptor accessory proteins (IL-1RAcP) to form the IL-33R. The interaction of IL-33 to its receptor activates NF-kB and MAP kinases and induces Th2 cytokines from in vitro polarized Th2 cells. In vivo, IL-33 promotes the expression of IL-4, IL-5, and IL-13. IL-33 acts as an inflammatory cytokine in Th2-type immune responses during asthma and atopic dermatitis. It is host-protective against helminth infections and reduces atherosclerosis by promoting Th2-type immune responses. Human aortic, coronary artery, and heart microvascular endothelial cells express mRNA for ST2L and sST2 isoforms, acting as a source for sST2 proteins. In fact, sST2 is considered as a prognostic biomarker in myocardial infarction and heart failure. In addition, sST2 has been associated with other human diseases including asthma with acute exacerbation, eosinophilic pneumonia, sepsis and trauma, and exacerbated idiopathic pulmonary fibrosis.

Molekulargewicht: The 550 amino acid recombinant protein has a predicted molecular mass of approximately 62 kDa. The DTT-reduced and non-reduced protein migrate approximately at 100 kDa and 200 kDa by SDS-PAGE. The predicted N-terminal amino acid is Lys.